Avalyn Pharma (AVLN)

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

的Avalyn Pharma Inc. Common Stock（AVLN）股票的价格今天是$27.73，自市场开启。该公司市值为$11.59亿，日交易量为$1.94万股。对于关注价格走势的投资者来说，Avalyn Pharma Inc. Common Stock股票今日的波动区间在$26.69和$27.87之间。前一交易日收盘价为 $26.82。

您准备好开始了吗？按照以下步骤操作，或阅读我们关于在Kraken上从10美元起购买Avalyn Pharma股票的指南。